Gilead Sciences Inc
Change company Symbol lookup
Select an option...
GILD Gilead Sciences Inc
CUTLF Canadian Utilities Ltd
JNJ Johnson & Johnson
MSI Motorola Solutions Inc
CCL Carnival Corp
MTWTF Metawater Co Ltd
ATRO Astronics Corp
HLT Hilton Worldwide Holdings Inc
MAIN Main Street Capital Corp
WIA Western Asset Inflation-Linked Income Fd
Go

Health Care : Biotechnology | Large Cap Value
Company profile

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Closing Price
$62.25
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
62.51
Day's Low
61.77
Volume
(Light)
Volume:
7,142,839

10-day average volume:
9,717,768
7,142,839

Display:

Providers:

UpdateCancel
6 providers
September 25, 2020
EUROPEAN COMMISSION GRANTS MARKETING AUTHORIZATION FOR JYSELECA(R) (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ACTIVE RHEUMATHOID ARTHRITIS

-- Jyseleca(R) Demonstrated Durable Efficacy Combined with a Consistent Safety Profile in Rheumatoid Arthritis Through 52 Weeks in Phase 3 Clinical Development Program -- Foster City, Calif., & Mechelen, Belgium, September 25, 2020, 19.00 CET...(Thomson Reuters ONE)

EUROPESE COMMISSIE VERLEENT HANDELSVERGUNNING VOOR JYSELECA(R) (FILGOTINIB) VOOR DE BEHANDELING VAN VOLWASSENEN MET MATIGE TOT ERNSTIGE REUMATOiDE ARTRITIS

-- Jyseleca(R) laat duurzame werkzaamheid en een consistent veiligheidsprofiel zien bij reumatoide artritis tot 52 weken in fase 3 klinisch ontwikkelingsprogramma -- Foster City, Calif., & Mechelen, Belgie, 25 september 2020, 19.00 CET - Gilead...(Thomson Reuters ONE)

European Commission Grants Marketing Authorization for Jyseleca(R) (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the European Commission (EC) has granted marketing authorization for Jyseleca(R) (filgotinib 200 mg and 100 mg tablets), a once-daily, oral...(BusinessWire)

Correction: Jyseleca(R) (filgotinib) goedgekeurd in Japan voor de behandeling van reumatoide artritis

Filgotinib laat duurzame werkzaamheid en een consistent veiligheidsprofiel zien tot 52 weken in klinische studies Mechelen, Belgie; 25 september 2020, 08.00 CET - Galapagos NV (Euronext & NASDAQ: GLPG) meldt dat samenwerkingspartner Gilead...(Thomson Reuters ONE)

Correction: Jyseleca(R) (filgotinib) approved in Japan for rheumatoid arthritis

Filgotinib demonstrates durable efficacy and consistent safety profile through 52 weeks in clinical trials Mechelen, Belgium; 25 September 2020, 08.00 CET - Galapagos NV (Euronext & NASDAQ: GLPG) reports that Gilead Sciences, Inc. (Nasdaq: GILD)...(Thomson Reuters ONE)

Jyseleca(R) (filgotinib) goedgekeurd in Japan voor de behandeling van reumatoide artritis

Filgotinib laat duurzame werkzaamheid en een consistent veiligheidsprofiel zien tot 52 weken in klinische studies Mechelen, Belgie; 25 september 2020, 08.00 CET - Galapagos NV (Euronext & NASDAQ: GLPG) meldt dat samenwerkingspartner Gilead...(Thomson Reuters ONE)

Jyseleca(R) (filgotinib) approved in Japan for rheumatoid arthritis

Filgotinib demonstrates durable efficacy and consistent safety profile through 52 weeks in clinical trials Mechelen, Belgium; 25 September 2020, 08.00 CET - Galapagos NV (Euronext & NASDAQ: GLPG) reports that Gilead Sciences, Inc. (Nasdaq: GILD)...(Thomson Reuters ONE)

Jyseleca(R) (Filgotinib) Approved in Japan for Rheumatoid Arthritis

Gilead Sciences, Inc. (Nasdaq: GILD) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted Gilead K.K. (Tokyo, Japan) regulatory approval of Jyseleca(R) (filgotinib 200 mg and...(BusinessWire)

September 24, 2020
Fish & Richardson Named 2020 Intellectual Property Boutique Firm of the Year by LMG Life Sciences; Wins Hatch-Waxman Impact Case of the Year

Fish & Richardson has been named the 2020 Intellectual Property Boutique Firm of the Year by LMG Life Sciences. Fish was also awarded the Hatch-Waxman Impact Case of the Year Award - the second time in three years - for its ongoing success for...(PR Newswire)

September 23, 2020
Gilead Sciences Prices $7.25 Billion of Senior Unsecured Notes

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the pricing of senior unsecured notes in an aggregate principal amount of $7.25 billion, in an underwritten, registered public offering, consisting of seven tranches: (BusinessWire)

September 20, 2020
(IMMU) Alert: Johnson Fistel Investigates Proposed Sale of Immunomedics; Is $88 a Fair Price?

Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Immunomedics Inc. (NASDAQ: IMMU) ("Immunomedics" or the "Company") breached their fiduciary duties in connection with the proposed sale...(PR Newswire)

September 18, 2020
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Immunomedics, Inc. - IMMU

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Immunomedics, Inc. ("Immunomedics" or the "Company") (IMMU)...(PR Newswire)

September 17, 2020
Cystic Fibrosis Market to Expand Profoundly at a CAGR of 24.4% and Reach USD 31.88 Billion by 2027; Increasing Awareness regarding CF to Lighten Sales Prospects, states Fortune Business Insights(TM)

Global cystic fibrosis market size is predicted to reach USD 31.88 billion by 2027, exhibiting a CAGR of 24.4% during the forecast period. The growing cases of respiratory and gastrointestinal infection among people can be a critical factor in...(Globe Newswire)

September 16, 2020
Nanomedicine Seen As A Promising Approach For Diagnosis and Treatment Against COVID

The National Institute for Health (NIH) is at the heart of the emerging and rapidly evolving war against the global pandemic. They constantly update the public on the latest information on research for a vaccine and therapies to fight the virus. A...(PR Newswire)

Cardiovascular Drugs Market to Exhibit a CAGR of 3.8% and Reach USD 63.96 Billion by 2026; Increasing Prevalence of Cardiovascular Diseases to Augment Growth, says Fortune Business Insights

Global cardiovascular drugs market is projected to reach USD 63.96 billion by 2026, exhibiting a CAGR of 3.8% during the forecast period. The increasing prevalence of heart stroke and cardiovascular diseases is one of the key reasons for the growth...(Globe Newswire)

September 15, 2020
Tizona Appoints Christine O'Brien as Chief Executive Officer

-- Transaction with Gilead Sciences Closed -- -- Tizona Advances TTX-080, a Novel Anti-HLA-G Antibody, with First Patients Treated in Phase I Study - Tizona Therapeutics, Inc., a clinical stage, privately held company developing first-in-class...(Globe Newswire)

Gilead's Magrolimab, an Investigational Anti-CD47 Monoclonal Antibody, Receives FDA Breakthrough Therapy Designation for Treatment of Myelodysplastic Syndrome

-- Additional Studies Are Evaluating Magrolimab in Both Hematologic and Solid Tumors -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for...(BusinessWire)

September 14, 2020
SHAREHOLDER ALERT: WeissLaw LLP Investigates Immunomedics, Inc.

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Immunomedics, Inc. ("IMMU" or the "Company") (NASDAQ: IMMU) in connection with the proposed acquisition of the Company by...(PR Newswire)

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Immunomedics, Inc. Buyout

Rigrodsky & Long, P.A. announces that it is investigating Immunomedics, Inc. ("Immunomedics") (NASDAQ GS: IMMU) regarding possible breaches of fiduciary duties and other violations of law related to Immunomedics' agreement to be acquired by...(Globe Newswire)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Immunomedics to Gilead Sciences

New York, New York--(Newsfile Corp. - September 14, 2020) - The following statement is being issued by Levi & Korsinsky, LLP: To view an enhanced version of this graphic, please...(Newsfile)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.